The emerging therapeutic role of antibody mixtures

Bibliography

• Li F, Vijayasankaran N, Shen AY, et al. Cell culture processes for monoclonal antibody production. MAbs 2010;2:466-79
   PubMed Web of Science ®Google Scholar
• Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007;12:1084-95
   PubMed Web of Science ®Google Scholar
• Robak T. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncol 2013;9(1):69-91
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37
   PubMed Web of Science ®Google Scholar
• Fagète S, Fischer N. Smarter drugs: a focus on pan-specific monoclonal antibodies. BioDrugs 2011;25:357-64
   Google Scholar
• Thakur A, Lum LG. Cancer therapy with bispecific antibodies: clinical experience. Curr Opin Mol Ther 2010;12:340-9
   PubMed Web of Science ®Google Scholar
• Choi BD, Kuan CT, Cai M, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA 2013;110:270-5
   PubMed Web of Science ®Google Scholar
• Fuentes G, Scaltriti M, Baselga J, et al. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011;13:R54
   PubMedGoogle Scholar
• Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 2013;27:35-53
   PubMed Web of Science ®Google Scholar
• Rasmussen SK, Næsted H, Müller C, et al. Recombinant antibody mixtures: production strategies and cost considerations. Arch Biochem Biophys 2012;526:139-45
   Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, et al. Phase ½ study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115:489-95
   PubMed Web of Science ®Google Scholar
• Robak T. Improving FCR immunochemotherapy in CLL. Blood 2010;115:437-8
   PubMed Web of Science ®Google Scholar
• Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113:2110-18
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Borjas-Almaguer OD, et al. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica 2012;97:717-22
   PubMed Web of Science ®Google Scholar
• Raju TS. Assessing Fc Glycan Heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC. Methods Mol Biol 2013;988:169-80
   PubMedGoogle Scholar
• Yusibov V, Streatfield SJ, Kushnir N, et al. Hybrid viral vectors for vaccine and antibody production in plants. Curr Pharm Des 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Rasmussen SK, Nielsen LS, Müller C, et al. Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes. BMC Proc 2011;5(Suppl 8):O2
   PubMedGoogle Scholar
• Frandsen TP, Naested H, Rasmussen SK, et al. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011;108:2171-81
   Google Scholar
• Skartved NJ, Jacobsen HJ, Pedersen MW, et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011;17:5962-72
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Jacobsen HJ, Koefoed K, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70:588-97
   PubMed Web of Science ®Google Scholar
• Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000;6:1302-13
   PubMed Web of Science ®Google Scholar
• Schindler J, Gajavelli S, Ravandi F, et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 2011;15:471-6
   Google Scholar
• Herrera L, Bostrom B, Gore L, et al. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936-41
   PubMed Web of Science ®Google Scholar
• Vallera DA, Chen H, Sicheneder AR, et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009;33:1233-42
   PubMed Web of Science ®Google Scholar
• Bakker AB, Marissen WE, Kramer RA, et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 2005;79:9062-8
   PubMed Web of Science ®Google Scholar
• Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008;26:5922-7
   PubMed Web of Science ®Google Scholar
• Kostense S, Moore S, Companjen A, et al. Validation of the rapid fluorescent focus inhibition test for rabies virus-neutralizing antibodies in clinical samples. Antimicrob Agents Chemother 2012;56:3524-30
   PubMed Web of Science ®Google Scholar
• Meyer K, Ng H, Parman T, et al. Nonclinical safety evaluation of XOMA 3AB, a novel triple monoclonal antibody drug product targeting botulinum toxin type A, in Sprague-Dawley Rats. Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Meeting; 10 – 12 January 2011; Washington
   Google Scholar
• Teshima G, Li MX, Danishmand R, et al. Separation of oxidized variants of a monoclonal antibody by anion-exchange. J Chromatogr A 2011;1218:2091-7
   Google Scholar
• Meng Q, Li M, Silberg MA, et al. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem 2012;421:351-61
   Google Scholar
• Nielsen LS, Baer A, Müller C, et al. Single-batch production of recombinant human polyclonal antibodies. Mol Biotechnol 2010;45:257-66
   Google Scholar
• Pedersen MW, Jacobsen HJ, Koefoed K, et al. Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70:588-97
   PubMed Web of Science ®Google Scholar
• Koefoed K, Steinaa L, Søderberg JN, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011;3:584-95
   PubMed Web of Science ®Google Scholar
• Dechant M, Weisner W, Berger S, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008;68:4998-5003
   PubMed Web of Science ®Google Scholar
• Andersen PS, Haahr-Hansen M, Coljee VW, et al. Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen. Mol Immunol 2007;44:412-22
   PubMed Web of Science ®Google Scholar
• Wiberg FC, Rasmussen SK, Frandsen TP, et al. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006;94:396-405
   PubMed Web of Science ®Google Scholar
• Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010;12:734-40
   PubMed Web of Science ®Google Scholar
• Robak T, Windyga J, Trelinski J, et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012;120:3670-6
   PubMed Web of Science ®Google Scholar
• de Kruif J, Kramer A, Nijhuis R, et al. Generation of stable cell clones expressing mixtures of human antibodies. Biotechnol Bioeng 2010;106:741-50
   PubMed Web of Science ®Google Scholar
• Rosati S, Thompson NJ, Barendregt A, et al. Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry. Anal Chem 2012;84:7227-32
   Google Scholar